Int J Mol Sci, 2025, 26(21):10609

Comparative Preclinical Evaluation of the Tumor-Targeting Properties of Radioiodine and Technetium-Labeled Designed Ankyrin Repeat Proteins for Imaging of Epidermal Growth Factor Receptor Expression in Malignant Tumors

Radionuclide molecular imaging of epidermal growth factor receptor (EGFR) expression might permit the selection of patients for EGFR-targeting therapies. Designed ankyrin repeat protein (DARPin) E01 with a high affinity to the ectodomain III of the EGFR is a possible EGFR imaging probe. The goal of this study was to evaluate the potential of radiolabeled DARPin E01 for in vivo imaging of EGFR. DARPin E01 containing the (HE)-tag was site-specifically labeled with a residualizing Tc (using Tc]Tc(CO)). Two methods providing non-residualizing I labels, direct electrophilic radioiodination and indirect radioiodination using [I]I--iodobenzoate (PIB), were tested. [Tc]Tc-(HE)-E01 and [I]I-(HE)-E01-PIB preserved specific binding to EGFR-expressing cells and affinity in the single-digit nanomolar range. Direct labeling with I resulted in a substantial loss of binding. In vitro cellular processing studies showed that both [Tc]Tc-(HE)-E01 and [I]I-(HE)-E01-PIB had rapid binding and relatively slow internalization. Evaluation of [Tc]Tc-(HE)-E01 biodistribution in normal CD1 mice showed that its hepatic uptake was non-saturable, suggesting that this tracer does not bind to murine EGFR. A side-by-side comparison of biodistribution and tumor targeting of [Tc]Tc-(HE)-E01 and [I]I-(HE)-E01-PIB was performed in Nu/j mice bearing EGFR-positive A-431 and EGFR-negative Ramos human cancer xenografts. Both radiolabeled DARPins demonstrated EGFR-specific tumor uptake. However, [I]I-(HE)-E01-PIB had appreciably lower uptake in normal organs compared to [Tc]Tc-(HE)-E01, which provided significantly (

Larkina M, Yanovich G, Hasnowo LA, Varvashenya R, Yuldasheva F, Tretyakova M, Plotnikov E, Zelchan R, Schulga A, Konovalova E, Ziganshin R, Belousov MV, Tolmachev V, Deyev SM

Department of immunology, Laboratory of molecular immunology, Group of mass spectrometry

: 10.3390/ijms262110609
Scopus: 2-s2.0-105021715964
: 41226646
IBCH: 12225
Ссылка на статью в журнале: https://www.mdpi.com/1422-0067/26/21/10609
Нет данных о цитировании
Данные статьи проверены модераторами 2025-11-19

Список научных проектов, где отмечена публикация

  1. Oncotheranostics and problems of resistance to antitumor and antibacterial drugs (April 23, 2024 — December 31, 2026). Deyev S.M., Alekseeva N.A., Alekseeva L.G., Aliper E.T., Alferova V.A., Andrianova A.G., Babkova Y.S., Baranova A.A., Baranova M.N., Belogurov A.A., Bogachuk A.P., Bocharov E.V., Burenina O.Y., Bychkov M.L., Veretenenko I.I., Volkov D.V., Gabibov A.G., Gordeeva V.D., Gorelik L.V., Gryaznova O.Y., Gulyak E.L., Deryabin A.S., Dobrochaeva K.L., Evpak A.S., Egorova N.S., Emel'yanov E.A., Ermolaeva E.O., Efremov R.G., Zhitlov M.Y., Zhuchkov V.A., Zakharova M.Y., Zvyagin A.V., Zelepukin I.V., Zinchenko A.A., Kalganova A.I., Kirichenko A.V., Kirpichnikov M.P., Knorre V.D., Kovaleva D.K., Kovalenko E.I., Kokaeva I.S., Konovalova E.V., Konshina A.G., Korotkova N.A., Korshun V.A., Kotel'nikova O.V., Kotelnikova P.A., Kravchenko T.V., Krylov N.A., Kudriaeva A.A., Kuzmina O., Kurbatskaya I.N., Lazarev I.V., Logvinov A.S., Lyukmanova E.N., Mazur R.V., Mallaev R.A., Mirzoeva N.Z., Mirkasymov A.B., Musatova O.E., Nechaeva A.M., Nikitin T.D., Nikonova A.V., Nolde D.E., Odzhomoko L.O., Orlova D.A., Panina I.S., Pakhomov A.A., Pahomova T.E., Pizhonkov N.A., Pipiya S.O., Polyansky A.A., Pohorukov D.A., Prokopenko Y.A., Proshkina G.M., Rodionov V.I., Rotanova T.V., Rubcov Y.P., Ryabukha Y.A., Savateeva N.S., Sapozhnikova K.A., Serova E.V., Sinichich A.A., Smirnov I.V., Sogomonyan A.S., Spallone A., Stepanova (Ukrainskaya) V.M., Streltsova M.A., Sutugin Y.A., Terekhov S.S., Frolova A.Y., Khavroshechkina E.V., Khodarovich Y.M., Kholodenko R.V., Tsetlin V.I., Chumakov S.P., Shilova P.A., Shlepova O.V., Shramova E.I., Shul'ga A.A.. Grant, Budget.
  2. CAN 24 3523 Pj. . Сommercial.